Home > Insider Trading > Filing (0001140361-13-034582)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1311596	Regado Biosciences Inc	RGDO	Pharmaceutical Preparations (2834)	030422069

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1579186	Partners Investment Rothschild De Edmond	47 Rue Du Faubourg Saint Honore Paris I0 75008		No	No	Yes	No
1579266	Biodiscovery 3, Fcpr	47 Rue Du Faubourg Saint Honore Paris I0 75401		No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock, Par Value $0.001 Per Share	Acquisiton	2013-08-27	1,021,930	$0.00	1,021,930	No	4	C	Direct
Common Stock, Par Value $0.001 Per Share	Acquisiton	2013-08-27	169,633	$0.00	1,191,563	No	4	C	Direct
Common Stock, Par Value $0.001 Per Share	Acquisiton	2013-08-27	1,215,708	$4.00	2,407,271	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	C	Direct
No	4	C	Direct
No	4	P	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock, Par Value $0.001 Per Share	Series D Preferred Stock	Disposition	2013-08-27	17,066,243	$0.00	1,021,930	$0.00
Common Stock, Par Value $0.001 Per Share	Series E Preferred Stock	Disposition	2013-08-27	2,832,872	$0.00	169,633	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Direct
0			No	4	C	Direct

Footnotes

The reportable securities are directly held by BioDiscovery 3, FCPR ("BioDiscovery"). Edmond de Rothschild Investment Partners, S.A.S. ("Edmond de Rothschild"), as the management company for BioDiscovery indirectly beneficially owns the reportable securities. Raphael Wisniewski is a partner at Edmond de Rothschild and a member of the board of directors of the Issuer. Edmond de Rothschild and Mr. Wisniewski disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest therein, and this report is not an admission that either Edmond de Rothschild or Mr. Wisniewski is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
The shares of Series D Preferred Stock had no expiration date and automatically converted upon the consummation of the initial public offering of Regado Biosciences, Inc. (the "Company") at a conversion ratio of 1 share of Series D Preferred Stock to 0.05988024 shares of common stock, for no additional consideration.
The shares of Series E Preferred Stock had no expiration date and automatically converted upon the consummation of the Company's initial public offering at a conversion ratio of 1 share of Series E Preferred Stock to 0.05988024 shares of common stock, for no additional consideration.